Factors Shaping the Implementation of Serious Illness Conversations: Frontline Clinician Insights.

In recent years, cannabis has gained worldwide recognition for its therapeutic, medicinal, and recreational potential. This plant, belonging to the genus Cannabis, contains a wide variety of compounds of interest, most notably terpenes and phytocannabinoids. Among the latter, cannabidiol (CBD) is one of the most relevant non-psychoactive phytocannabinoids of L., extensively studied for its therapeutic properties in the treatment of neurological disorders, anxiety, inflammation, and chronic pain [,,,]. Determining CBD in commercial samples is crucial today due to the rapid growth of the cannabis-derived products market and the wide variety of available formulations, including oils, extracts, cosmetics, food, and therapeutic products. The actual CBD concentration directly influences the product’s efficacy, safety, and economic value, making its reliable quantification essential for both regulatory compliance and ensuring transparency for consumers. Therefore, having robust, rapid, and reproducible analytical methods enables the verification of authenticity, the detection of adulteration, and the evaluation of overall quality in commercial products, thus providing indispensable scientific support for industry and regulatory agencies [,,,,]. Currently, the identification and quantification of cannabinoids are performed using high-performance analytical techniques such as high-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), and their combinations (GC-MS, LC-MS), as well as NMR spectroscopy. Although these techniques are highly accurate and reliable, they have significant disadvantages, including high cost, the use of large quantities of solvents, the need for specialized personnel, and lengthy analysis times [,,].